drugset / Trial / NCT01237873
Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of the combination of aliskiren and amlodipine given to patients with essential hypertension. This study is being conducted to support registration of the fixed combination of aliskiren/amlodipine in the treatment for hypertension in Japan.
Timeline
- Start
- 2011-01
- Primary completion
- 2012-02
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aliskiren | Small molecule | 150 mg | — |
| Subject | Amlodipine | Other / unclassified | 2.5 mg | — |
| Subject | Amlodipine | Other / unclassified | 5 mg | — |